Isis Pharmaceuticals Gets $1.4M From Alnylam

Carlsbad-based biopharmaceuticals firm Isis Pharmaceuticals, which is developing treatments for Crohn's disease and other rare diseases, said this morning that it will receive $1.4M from Alnylam Pharmaceuticals. The payment comes as part of a collaboration between the two companies in the area of agriculture. Isis said the deal also includes potential future royalty payments and future milestone payments. The two companies have been in a strategic relationships since 2004 around RNAi technology.